Updated data from the RAMP 205 trial show that Verastem's potential first-in-class oral RAF/MEK clamp inhibitor avutometinib plus defactinib, layered on top of gemcitabine and nab-paclitaxel, produced a 52% confirmed objective response rate and an 86% six-month overall survival rate in 29 patients with first-line metastatic pancreatic ductal adenocarcinoma. The results, if they hold at maturity, would position Boston-based Verastem Oncology (Nasdaq: VSTM) as one of the more credible entrants in a field that has resisted nearly every targeted approach attempted over the past decade.
The data carry the usual caveats of a small, single-arm Phase Ib/IIa cohort with a median follow-up of 9.8 months and immature overall survival. Cross-trial comparisons are limited by differences in patient selection, study design, and follow-up duration. But the 52% ORR and 83% tumor shrinkage rate compare favorably against the pivotal MPACT trial benchmark of roughly 23% for gemcitabine plus nab-paclitaxel alone, and the 68% six-month progression-free survival rate similarly exceeds historical expectations for standard chemotherapy in this setting.
The mechanistic rationale for the combination is straightforward: KRAS mutations drive more than 90% of pancreatic cancers, activating the RAS/MAPK signaling cascade. Avutometinib functions as a RAF/MEK clamp, blocking MEK kinase activity while preventing compensatory upstream reactivation through RAF. That blockade, however, tends to trigger FAK-mediated resistance. Defactinib, a FAK inhibitor, is designed to suppress that escape mechanism. The hypothesis is that simultaneous disruption of both the primary oncogenic signal and its principal resistance pathway, combined with cytotoxic chemotherapy, produces more durable tumor control than chemotherapy alone.
Competitive context
The pancreatic cancer first-line landscape is crowded with investigational programs, several of which have reported data around the same period. Immuneering Corporation (Nasdaq: IMRX) reported a 17.3-month median overall survival in 55 patients treated with its MEK inhibitor atebimetinib plus modified gemcitabine/nab-paclitaxel, and has advanced into the Phase III MAPKeeper 301 trial. Revolution Medicines (Nasdaq: RVMD) presented daraxonrasib, an oral RAS(ON) multi-selective inhibitor, in combination with gemcitabine/nab-paclitaxel, showing a 58% ORR and a 90% six-month OS rate in 40 patients — data that have now advanced into the Phase III RASolute 303 trial. The avutometinib/defactinib ORR of 52% and six-month OS of 86% are broadly consistent with these signals, though none of these datasets can be meaningfully ranked against each other without randomized comparisons.
The approved first-line standard of care remains gemcitabine plus nab-paclitaxel, established in the MPACT trial with a median OS of approximately 8.5 months, and Ipsen's Onivyde (irinotecan liposome) as part of the NALIRIFOX regimen, which demonstrated a median OS of 11.1 months in the NAPOLI-3 trial and received US FDA approval in February 2024. No targeted therapy has yet been approved for unselected first-line metastatic PDAC.